Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays

Documenti analoghi

• Monitoring of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Sensitizing and Resistance Mutations in the Plasma DNA of Patients With Advanced Non–Small Cell Lung Cancer During Treatment With Erlotinib
  di: Sorensen, Boe S, et al.
  Pubblicazione: (2014)
• The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
  di: Demuth, Christina, et al.
  Pubblicazione: (2018)
• Detection of EGFR mutation in plasma using multiplex allele-specific PCR (MAS-PCR) and surface enhanced Raman spectroscopy
  di: Li, Xiaozhou, et al.
  Pubblicazione: (2017)
• Real-Time Quantitative PCR of Microdissected Paraffin-Embedded Breast Carcinoma : An Alternative Method for HER-2/neu Analysis
  di: Gjerdrum, Lise Mette, et al.
  Pubblicazione: (2004)
• Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients()
  di: Winther-Larsen, Anne, et al.
  Pubblicazione: (2016)